Last edition
News about "BioArctic "
US FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer's Disease
The US Food and Drug Administration (FDA) has approved Leqembi Iqlik (lecanemab-irmb) as a once-weekly subcutaneous starting dose for early Alzheimer's Disease (AD), with a U.S. launch planned for August 2026.
BioArctic | 14/07/2026 | By News Bureau
BioArctic and Lilly Sign Collaboration and Research Agreement for BrainTransporter-Based Therapy
BioArctic and Lilly have entered a research and collaboration agreement to combine a Lilly compound with BioArctic’s BrainTransporter technology. BioArctic will receive a USD 30 million upfront payment under the deal.
BioArctic | 24/06/2026 | By News Bureau
China Grants Priority Review to Leqembi Subcutaneous BLA
The Priority Review and Approval Procedure has been implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this procedure, the assessment period is expected to be shortened.
BioArctic | 11/02/2026 | By News Bureau | 162
China Adds Leqembi to Innovative Drug Insurance List
BioArctic’s partner Eisai said Leqembi has been added to China’s new Commercial Insurance Innovative Drug List, a move by the NHSA that broadens access to the Alzheimer’s therapy for patients in the early stages of the disease.
BioArctic | 09/12/2025 | By Akanki | 325
Health Canada Grants Authorisation for Leqembi (Lecanemab)
BioArctic has the right to commercialise Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialisation in the region.
BioArctic | 28/10/2025 | By Dineshwori | 254
This marks the third collaboration BioArctic has entered into with partners using the BrainTransporter technology.
BioArctic | 27/08/2025 | By Dineshwori | 447
Novartis Expands Collaboration with BioArctic, Eyes Licensing Opportunity Worth Up to $772 Million
The partnership focuses on combining BioArctic’s BrainTransporter technology with a Novartis proprietary antibody to develop a novel drug candidate. Should Novartis proceed, it would take full responsibility for the candidate’s global development and commercialization.
BioArctic | 26/08/2025 | By Darshana | 383
Leqembi sBLA for Alzheimers IV Maintenance Moves Forward with FDA
Eisai has submitted a supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb intravenous (IV) maintenance dosing to the US Food and Drug Administration (FDA).
BioArctic | 01/04/2024 | By Manvi | 679
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy